Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Trial Details

NCT ID
NCT05732831
Phase
PHASE1 / PHASE2
Sponsor
Tango Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • TNG462
  • Pembrolizumab
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302
  • Grand Junction, Colorado, United States|39.06387,-108.55065
  • Lake Mary, Florida, United States|28.75888,-81.31784
  • Miami, Florida, United States|25.77427,-80.19366
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Age: ≥18 years-of-age at the time of signature of the main study ICF
  • Performance status: ECOG Performance Score of 0 to 1
  • Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor
  • Prior standard therapy, as available

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →